ppanPersonalized Psychiatry and NeurologyPersonalized Psychiatry and Neurology2712-9179V. M. Bekhterev National Medical Research Centre for Psychiatry and Neurology of the Ministry of Health of the Russian Federation (Bekhterev NMRC PN)10.52667/2712-9179-2026-6-2-56-60ppan-180Research ArticleARTICLEScreening for mutations in the GBA1 and LRRK2 genes in schizophrenia in the Northwestern region of RussiaSyryevaOlesya V.

Gatchina

LavrinovaAnna O.

Gatchina

Saint Petersburg

DemidovaEvgenia A.

Gatchina

PidyurchinaVictoria N.

Gatchina

UsenkoTatyana S.

Gatchina

Saint Petersburg

KrapovaAnna K.

Gatchina

MoshkovskayaAlexandra O.

Saint Petersburg

ZalutskayaNatalia M.

Saint Petersburg

NasyrovaRegina F.

Saint Petersburg

NeznanovNikolay G.

Saint Petersburg

PchelinaSofya N.

Gatchina

Saint Petersburg

EmelyanovAnton K.

Tel.: +7 (81371) 4-60-93

Gatchina

Saint Petersburg

e_anton_gen@mail.ruPetersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute»Russian FederationPetersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute»; Pavlov First Saint Petersburg State Medical UniversityRussian FederationV.M. Bekhterev National Medical Research Centre for Psychiatry and NeurologyRussian Federation202624062026625660Copyright © Syryeva O.V., Lavrinova A.O., Demidova E.A., Pidyurchina V.N., Usenko T.S., Krapova A.K., Moshkovskaya A.O., Zalutskaya N.M., Nasyrova R.F., Neznanov N.G., Pchelina S.N., Emelyanov A.K., 20262026Syryeva O.V., Lavrinova A.O., Demidova E.A., Pidyurchina V.N., Usenko T.S., Krapova A.K., Moshkovskaya A.O., Zalutskaya N.M., Nasyrova R.F., Neznanov N.G., Pchelina S.N., Emelyanov A.K.Syryeva O.V., Lavrinova A.O., Demidova E.A., Pidyurchina V.N., Usenko T.S., Krapova A.K., Moshkovskaya A.O., Zalutskaya N.M., Nasyrova R.F., Neznanov N.G., Pchelina S.N., Emelyanov A.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.jppn.ru/jour/article/view/180

Schizophrenia (SCZ) is a severe mental disorder which exact pathogenesis remains unknown. The disorder has been linked to disturbances in lipid metabolism and lysosomal function. A link between this disorder and Parkinson's disease (PD) is suggested. Pathogenic mutations in the GBA1 gene, which lead to dysfunction of the lysosomal enzyme glucocerebrosidase, are a highrisk factor of PD. Meanwhile, mutations in the LRRK2 gene are the most common cause of hereditary forms of PD and may indirectly affect the activity of this enzyme. GBA1and LRRK2related PD are the most prevalent forms of the disease known today. Materials and Methods: In this study, we used PCR-RFLP and real-time PCR allelic discrimination to assess the frequency of mutations in the LRRK2 (G2019S) and GBA1 (N370S, L444P, E326K) genes among 161 SCZ patients and 434 control individuals residing in the Northwestern region of Russia. Results: The study found no association between the investigated mutations and the risk of SCZ. Among SCZ patients, no carriers of the N370S mutation in the GBA1 gene or the G2019S mutation in the LRRK2 gene were identified. The frequency of GBA1 mutations (L444P+N370S+E326K) among SCZ patients was found to be 3.2%. Conclusions: Thus, this study demonstrated that mutations in the GBA1 gene are not associated with the risk of SCZ.

SchizophreniaParkinson's diseasemutations in the GBA1 and LRRK2 genes.The research was carried out within the state assignment of Ministry of Science and Higher Education of the Russian Federation (theme №1023031500037-7-1.6.8;1.6.1;1.6.2;1.6.3).ReferencesKuusimäki T., Al-Abdulrasul H., Kurki S., et al. Increased risk of Parkinson’s disease in patients with schizophrenia spec-trum disorders. Mov Disord. 2021; 36(6): 1353–1561. https://doi.org/10.1002/mds.28484Kuusimäki T., Al-Abdulrasul H., Kurki S., et al. Increased risk of Parkinson’s disease in patients with schizophrenia spec-trum disorders. Mov Disord. 2021; 36(6): 1353–1561. https://doi.org/10.1002/mds.28484Grover S., Sahoo S., Goyal M.K. Schizophrenia with comorbid idiopathic Parkinson’s disease: A difficult clinical management scenario. Indian J Psychol Med. 2017; 39(6): 823–7. https://doi.org/10.4103/IJPSYM.IJPSYM_68_17Grover S., Sahoo S., Goyal M.K. Schizophrenia with comorbid idiopathic Parkinson’s disease: A difficult clinical management scenario. Indian J Psychol Med. 2017; 39(6): 823–7. https://doi.org/10.4103/IJPSYM.IJPSYM_68_17Vashenko A.V., Ziatyeva A.P. Parkinson's disease and schizophrenia: etyology and alternative approach to the treatment. University Clinic. 2017; 3-2 (24): 34-39. (In Russ.).Vashenko A.V., Ziatyeva A.P. Parkinson's disease and schizophrenia: etyology and alternative approach to the treatment. University Clinic. 2017; 3-2 (24): 34-39. (In Russ.).Sharma S., Aggarwal N. Idiopathic Parkinson’s disease and schizophrenia: dilemma in diagnosis and treatment of a case. Iran J Psychiatry. 2019; 14(2): 179–81.Sharma S., Aggarwal N. Idiopathic Parkinson’s disease and schizophrenia: dilemma in diagnosis and treatment of a case. Iran J Psychiatry. 2019; 14(2): 179–81.Kopytova A.E., Neznanov N.G., Zalutskaya N.M., et al. Elevated level of blood lyso-sphingolipids in patients with schizophrenia. Russian Journal of Genetics. 2023; 59(6): 670-675. https://doi.org/10.31857/S0016675823060085. (In Russ.).Kopytova A.E., Neznanov N.G., Zalutskaya N.M., et al. Elevated level of blood lyso-sphingolipids in patients with schizophrenia. Russian Journal of Genetics. 2023; 59(6): 670-675. https://doi.org/10.31857/S0016675823060085. (In Russ.).Usenko T., Bezrukova A., Basharova K., et al. Altered sphingolipid hydrolase activities and alpha-synuclein level in late-onset schizophrenia. Metabolites. 2023; 14(1): 30. https://doi.org/10.3390/metabo14010030Usenko T., Bezrukova A., Basharova K., et al. Altered sphingolipid hydrolase activities and alpha-synuclein level in late-onset schizophrenia. Metabolites. 2023; 14(1): 30. https://doi.org/10.3390/metabo14010030Mistry P.K., Lopez G., Schiffmann R., et al. Gaucher disease: Progress and ongoing challenges. Mol Genet Metab. 2017; 120(1–2): 8–21. https://doi.org/10.1016/j.ymgme.2016.11.006Mistry P.K., Lopez G., Schiffmann R., et al. Gaucher disease: Progress and ongoing challenges. Mol Genet Metab. 2017; 120(1–2): 8–21. https://doi.org/10.1016/j.ymgme.2016.11.006Staretz-Chacham O., Choi J.H., Wakabayashi K., et al. Psychiatric and behavioral manifestations of lysosomal storage disorders. Am J Med Genet B Neuropsychiatr Genet. 2010; 153B(7): 1253–1265. https://doi.org/10.1002/ajmg.b.31097Staretz-Chacham O., Choi J.H., Wakabayashi K., et al. Psychiatric and behavioral manifestations of lysosomal storage disorders. Am J Med Genet B Neuropsychiatr Genet. 2010; 153B(7): 1253–1265. https://doi.org/10.1002/ajmg.b.31097Koros C., Bougea A., Alefanti I., et al. A global perspective of GBA1-related Parkinson’s disease: A narrative review. Genes. 2024; 15(12): 1605. https://doi.org/10.3390/genes15121605Koros C., Bougea A., Alefanti I., et al. A global perspective of GBA1-related Parkinson’s disease: A narrative review. Genes. 2024; 15(12): 1605. https://doi.org/10.3390/genes15121605Sanyal A., DeAndrade M.P., Novis H.S., et al. Lysosome and inflammatory defects in GBA1-mutant astrocytes are normalized by LRRK2 inhibition. Mov Disord. 2020; 35(5): 760-773. https://doi.org/10.1002/mds.27994Sanyal A., DeAndrade M.P., Novis H.S., et al. Lysosome and inflammatory defects in GBA1-mutant astrocytes are normalized by LRRK2 inhibition. Mov Disord. 2020; 35(5): 760-773. https://doi.org/10.1002/mds.27994Ysselstein D., Nguyen M., Young T. J., et al. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson’s disease patients. Nat Commun. 2019; 10(1): 5570. https://doi.org/10.1038/s41467-019-13413-wYsselstein D., Nguyen M., Young T. J., et al. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson’s disease patients. Nat Commun. 2019; 10(1): 5570. https://doi.org/10.1038/s41467-019-13413-wFerrazza R., Cogo S., Melrose H., et al. LRRK2 deficiency impacts ceramide metabolism in brain. Biochem Biophys Res Commun. 2016; 478(3): 1141-1146. https://doi.org/10.1016/j.bbrc.2016.08.082Ferrazza R., Cogo S., Melrose H., et al. LRRK2 deficiency impacts ceramide metabolism in brain. Biochem Biophys Res Commun. 2016; 478(3): 1141-1146. https://doi.org/10.1016/j.bbrc.2016.08.082Singh A., Zhi L., Zhang H. LRRK2 and mitochondria: Recent advances and current views. Brain Res. 2019; 1702: 96–104. https://doi.org/10.1016/j.brainres.2018.06.010Singh A., Zhi L., Zhang H. LRRK2 and mitochondria: Recent advances and current views. Brain Res. 2019; 1702: 96–104. https://doi.org/10.1016/j.brainres.2018.06.010Whitehurst T., Howes O. The role of mitochondria in the pathophysiology of schizophrenia: A critical review of the evidence focusing on mitochondrial complex one. Neurosci Biobehav Rev. 2022; 132: 449–464. https://doi.org/10.1016/j.neubiorev.2021.11.047Whitehurst T., Howes O. The role of mitochondria in the pathophysiology of schizophrenia: A critical review of the evidence focusing on mitochondrial complex one. Neurosci Biobehav Rev. 2022; 132: 449–464. https://doi.org/10.1016/j.neubiorev.2021.11.047Emelyanov A.K., Usenko T.S., Tesson C., et al. Mutation analysis of Parkinson’s disease genes in a Russian data set. Neu-robiol Aging. 2018; 71: 267.e7-267.e10. https://doi.org/10.1016/j.neurobiolaging.2018.06.027Emelyanov A.K., Usenko T.S., Tesson C., et al. Mutation analysis of Parkinson’s disease genes in a Russian data set. Neu-robiol Aging. 2018; 71: 267.e7-267.e10. https://doi.org/10.1016/j.neurobiolaging.2018.06.027Velayati A., Yu W.H., Sidransky E. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep. 2010; 10(3): 190–8. https://doi.org/10.1007/s11910-010-0102-xVelayati A., Yu W.H., Sidransky E. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep. 2010; 10(3): 190–8. https://doi.org/10.1007/s11910-010-0102-xSenkevich K.A., Kopytova A.E., Usenko T.S., et al. Parkinson’s disease associated with GBA gene mutations: Molecular aspects and potential treatment approaches. Acta Naturae. 2021; 13(2): 70–78. https://doi.org/10.32607/actanaturae.11031Senkevich K.A., Kopytova A.E., Usenko T.S., et al. Parkinson’s disease associated with GBA gene mutations: Molecular aspects and potential treatment approaches. Acta Naturae. 2021; 13(2): 70–78. https://doi.org/10.32607/actanaturae.11031Pankratz N., Beecham G.W., DeStefano A.L., et al. Meta-analysis of Parkinson’s disease: identification of a novel locus, RIT2. Ann Neurol. 2012; 71(3): 370–384. https://doi.org/10.1002/ana.22687Pankratz N., Beecham G.W., DeStefano A.L., et al. Meta-analysis of Parkinson’s disease: identification of a novel locus, RIT2. Ann Neurol. 2012; 71(3): 370–384. https://doi.org/10.1002/ana.22687Mallett V., Ross J.P., Alcalay R.N., et al. GBA p.T369M substitution in Parkinson disease: Polymorphism or association? A meta-analysis. Neurol Genet. 2016; 2(5): e104. https://doi.org/10.1212/NXG.0000000000000104Mallett V., Ross J.P., Alcalay R.N., et al. GBA p.T369M substitution in Parkinson disease: Polymorphism or association? A meta-analysis. Neurol Genet. 2016; 2(5): e104. https://doi.org/10.1212/NXG.0000000000000104Chahine L.M., Qiang J., Ashbridge E., et al. Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. JAMA Neurol. 2013; 70(7): 852–858. https://doi.org/10.1001/jamaneurol.2013.1274Chahine L.M., Qiang J., Ashbridge E., et al. Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. JAMA Neurol. 2013; 70(7): 852–858. https://doi.org/10.1001/jamaneurol.2013.1274Brockmann K., Srulijes K., Hauser A.K., et al. GBA-associated PD presents with nonmotor characteristics. Neurology. 2011; 77(3): 276–280. https://doi.org/10.1212/WNL.0b013e318225ab77Brockmann K., Srulijes K., Hauser A.K., et al. GBA-associated PD presents with nonmotor characteristics. Neurology. 2011; 77(3): 276–280. https://doi.org/10.1212/WNL.0b013e318225ab77Alcalay R.N., Caccappolo E., Mejia-Santana H. et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology. 2012; 78(18): 1434–1440. https://doi.org/10.1212/WNL.0b013e318253d54bAlcalay R.N., Caccappolo E., Mejia-Santana H. et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology. 2012; 78(18): 1434–1440. https://doi.org/10.1212/WNL.0b013e318253d54bAlcalay R.N., Levy O.A., Waters C.C., et al. Glucocerebrosidase activity in Parkinson’s disease with and without GBA mutations. Brain. 2015; 138(Pt 9): 2648–2658. https://doi.org/10.1093/brain/awv179Alcalay R.N., Levy O.A., Waters C.C., et al. Glucocerebrosidase activity in Parkinson’s disease with and without GBA mutations. Brain. 2015; 138(Pt 9): 2648–2658. https://doi.org/10.1093/brain/awv179Trakadis Y.J., Fulginiti V., Walterfang M. Inborn errors of metabolism associated with psychosis: literature review and case-control study using exome data from 5090 adult individuals. J Inherit Metab Dis. 2018; 41(4): 613–21. https://doi.org/10.1007/s10545-017-0023-9Trakadis Y.J., Fulginiti V., Walterfang M. Inborn errors of metabolism associated with psychosis: literature review and case-control study using exome data from 5090 adult individuals. J Inherit Metab Dis. 2018; 41(4): 613–21. https://doi.org/10.1007/s10545-017-0023-9Mata I. F., Wedemeyer W. J., Farrer M. J., et al. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 2006; 29(5): 286-293. https://doi.org/10.1016/j.tins.2006.03.006Mata I. F., Wedemeyer W. J., Farrer M. J., et al. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 2006; 29(5): 286-293. https://doi.org/10.1016/j.tins.2006.03.006Zhao Y., Ho P., Yih Y., et al. LRRK2 variant associated with Alzheimer’s disease. Neurobiol Aging. 2011; 32(11): 1990–3. https://doi.org/10.1016/j.neurobiolaging.2009.11.019Zhao Y., Ho P., Yih Y., et al. LRRK2 variant associated with Alzheimer’s disease. Neurobiol Aging. 2011; 32(11): 1990–3. https://doi.org/10.1016/j.neurobiolaging.2009.11.019Hui K. Y., Fernandez-Hernandez H., Hu J., et al. Functional variants in the LRRK2 gene confer shared effects on risk for Crohn's disease and Parkinson's disease. Sci Transl Med. 2018; 10(423): eaai7795. https://doi.org/10.1126/scitranslmed.aai7795Hui K. Y., Fernandez-Hernandez H., Hu J., et al. Functional variants in the LRRK2 gene confer shared effects on risk for Crohn's disease and Parkinson's disease. Sci Transl Med. 2018; 10(423): eaai7795. https://doi.org/10.1126/scitranslmed.aai7795Saunders-Pullman R., Barrett M.J., Stanley K.M., et al. LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease. Mov Disord. 2010; 25(15): 2536-2541. https://doi.org/10.1002/mds.23314Saunders-Pullman R., Barrett M.J., Stanley K.M., et al. LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease. Mov Disord. 2010; 25(15): 2536-2541. https://doi.org/10.1002/mds.23314Buck S. A., Sanders L. H. LRRK2-mediated mitochondrial dysfunction in Parkinson's disease. Biochem J. 2025; 482(11): 721-739. https://doi.org/10.1042/BCJ20253062Buck S. A., Sanders L. H. LRRK2-mediated mitochondrial dysfunction in Parkinson's disease. Biochem J. 2025; 482(11): 721-739. https://doi.org/10.1042/BCJ20253062Li X., Zhang W., Zhang C., et al. No association between genetic variants of the LRRK2 gene and schizophrenia in Han Chinese. Neurosci Lett. 2014; 566: 210–215. https://doi.org/10.1016/j.neulet.2014.03.006Li X., Zhang W., Zhang C., et al. No association between genetic variants of the LRRK2 gene and schizophrenia in Han Chinese. Neurosci Lett. 2014; 566: 210–215. https://doi.org/10.1016/j.neulet.2014.03.006

The authors declare that there are no conflicts of interest present.